Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

mong existing oral OAB treatments, according to Dr. Sand. "Watson's oxybutynin gel is an elegant topical formulation that is clear, odorless and fast drying and will offer healthcare providers a unique treatment option for OAB patients," said Dr. Sand.

The Phase 3 multi-center, double blind, placebo-controlled study evaluated the efficacy and safety of OTG in 789 patients with overactive bladder. The primary objective of the study was to demonstrate that daily treatment of a 1g dose (approximately 1 mL) of OTG for 12 weeks was superior to placebo for the relief of OAB symptoms. Changes from baseline to endpoint were calculated from a three-day patient urinary diary and included a reduction in incontinence episodes and urinary frequency, and an increase in void volume. Additionally, 216 patients participated in a 14-week, open label, safety-extension study for a total of 26 weeks. During the double-blind portion of the trial, highly statistically significant improvements relative to placebo were seen on all of these endpoints.

Secondary endpoints also included a patient assessment of incontinence-specific, quality-of-life measures using multiple validated instruments including the Incontinence Impact Questionnaire (IIQ) and the King's Health Questionnaire, which indicated a significant positive effect of OTG treatment on quality-of-life total and subscale scores at endpoint in comparison with placebo.

OTG was well tolerated in the study. No serious adverse events related to the treatment were reported. Dry mouth (6.9%) and application site pruritis (2.1%) were the only treatment-related side effects reported at levels greater than 2%. Treatment-related adverse events that resulted in study discontinuation during the double-blind period were low (1.8%) and the similar for both the treatment and placebo groups.

Phase 1 studies have demonstrated that the steady-state plasma levels of oxybutynin show little fluctuation during the 24-hour dosin
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Cryoport, Inc. ... "Company"), the leading provider of advanced cryogenic ... serving markets including immunotherapies, stem cells, cell ... health, and reproductive medicine, announced today that ... common stock and warrants (the "Units") under a registered ...
(Date:7/29/2015)... Colo., July 29, 2015 Heska Corporation ... a provider of advanced veterinary diagnostic and other specialty ... quarter ended June 30, 2015. Second Quarter ... Operations was up nearly 100% to $1.829 million, from $917 ... to $10.1 million, from $7.8 million. , Core Companion ...
(Date:7/29/2015)... , July 27, 2015 Research and ... of the "Global Neurostimulation Devices Market 2015" ... analysts forecast the global neurostimulation devices market to ... period 2014-2019. The report, Global Neurostimulation ... an in-depth market analysis with inputs from industry ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Heska Reports Financial Results for the Second Quarter of 2015 2Heska Reports Financial Results for the Second Quarter of 2015 3Heska Reports Financial Results for the Second Quarter of 2015 4Heska Reports Financial Results for the Second Quarter of 2015 5Heska Reports Financial Results for the Second Quarter of 2015 6Heska Reports Financial Results for the Second Quarter of 2015 7Heska Reports Financial Results for the Second Quarter of 2015 8Global Neurostimulation Devices Market 2015-2019 2
... NEW YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: ... paper published in Nucleic,Acids Research by a group ... ability of furamidine to inhibit a key enzyme ... Furamidine is the active metabolite (DB75),of Immtech,s proprietary, ...
... Scheduled Start of Phase 3 Clinical Trial, BELTSVILLE, ... has reported a second quarter 2007 loss from continuing,operations ... to a loss from,continuing operations of $699,000, or 5 ... from discontinued operations in the second quarter,of 2007 was ...
Cached Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3Spherix Reports Second Quarter Earnings 2
(Date:7/29/2015)... Plains, NJ (PRWEB) , ... July 29, 2015 , ... ... , Dr. Andrzej Klos, a board-certified pediatrician for nearly 38 years, is motivated each ... work, dedication and commitment to his profession shine alongside his many awards and accolades, ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the The ... legal, and are exposed to advertisements, for medicinal use are more likely to abuse ... where the use of marijuana is considered beneficial are more apt to use the ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Angelo’s FabriClean, ... its new service: water damage restoration of carpets and rugs. The company will now ... as for commercial clients. , An overflowing overhead tank, rain leaking through an ...
(Date:7/29/2015)... Park, Pa. (PRWEB) , ... July 29, 2015 ... ... education services for autism. Parents, educators and service providers of children living with ... practices to better serve the growing demographic. , The National Autism Conference ...
(Date:7/29/2015)... ... July 29, 2015 , ... Topical BioMedics, Inc., ... Pain Relief and Healing Cream designated as the nonprofit’s natural pain reliever of ... addressing Line of Duty Deaths (LODD) and the high rate of pain and ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Angelo’s FabriClean Now Offers Water Damage Restoration For Residential and Commercial Accounts 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6
... Cholesterol-lowering meds linked to less tumor inflammation, research ... Cholesterol-lowering statins significantly reduce prostate tumor inflammation, which ... new study findings suggest. , Duke University Medical ... before prostate cancer surgery was associated with a ...
... Consideration of patient,s needs and beliefs helps preserve relationship, ... When a patient asks for a treatment that a ... very, very carefully. , Television advertising of prescription medicines ... inappropriate for them. And new research finds that taking ...
... ... ... ... ...
... ... ... ... ...
... COLUMBIA, Mo. Thousands of men, women and ... the U.S. Department of Justice. Traditionally, therapy for ... trauma and pain. In contrast, a University of ... survivors through highlighting their resilience, resourcefulness, and ability ...
... ... ... , ... , , , ...
Cached Medicine News:Health News:Statins May Benefit Prostate Cancer Patients 2Health News: Doctors Have Many Ways to Say 'No' 2Health News: Doctors Have Many Ways to Say 'No' 3Health News:Los Angeles Jewish Home Adds Short-Term Rehabilitative Care to Family of Services 2Health News:Los Angeles Jewish Home Adds Short-Term Rehabilitative Care to Family of Services 3Health News:Los Angeles Jewish Home Adds Short-Term Rehabilitative Care to Family of Services 4Health News:Heska Announces Q4 and Annual 2009 Results 2Health News:Heska Announces Q4 and Annual 2009 Results 3Health News:Heska Announces Q4 and Annual 2009 Results 4Health News:Heska Announces Q4 and Annual 2009 Results 5Health News:Heska Announces Q4 and Annual 2009 Results 6Health News:Heska Announces Q4 and Annual 2009 Results 7Health News:Heska Announces Q4 and Annual 2009 Results 8Health News:Husbands' hostile, anti-social behaviors increase wives' symptoms of depression, researchers find 2Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 2Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 3Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 4
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... first microplate spectrophotometer designed specifically to run ... week. With rugged hardware, proven optical performance ... barrier of traditional spectrophotometry to obtain results ... easily read up to eight, 1 cm ...
... 1100RS Spectrophotometers are simple, ... for use in many ... educational, clinical, industrial and ... COD vial holders, Windows ...
Medicine Products: